Epitalon (also spelled Epithalon; abbreviation AEDG) is a synthetic tetrapeptide with the structure Ala-Glu-Asp-Gly (alanine-glutamic acid-aspartic acid-glycine). It was developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson as a simplified synthetic analogue of epithalamin, a polypeptide extract of the pineal gland from cattle. The idea was to reproduce the biological activity of the natural peptide complex within a short, well-defined, reproducible molecule [1].
In the scientific literature Epitalon is treated as a member of the short peptide bioregulators (Khavinson peptides) and as a model compound for studying the biology of ageing, telomerase regulation, and neuroendocrine rhythms [1][2].
What it is and its class
Epitalon is a linear tetrapeptide of four amino-acid residues, molecular formula C₁₄H₂₂N₄O₉, molar mass about 390 g/mol. By classification it belongs to the pineal-derived peptide bioregulators. Unlike native epithalamin, which is a mixture of peptides, Epitalon has a precisely defined sequence, which makes it a convenient and reproducible tool for laboratory research [1].
Mechanism of action
The best-studied effect concerns telomerase. In a culture of telomerase-negative human fetal fibroblasts, adding Epitalon induced expression of the catalytic subunit of telomerase (hTERT), raised the enzyme's activity, and was accompanied by telomere lengthening [2]. This became the basis for the hypothesis of a possible geroprotective role at the cellular level.
Researchers also describe antioxidant, antimutagenic, and neuroendocrine effects for Epitalon, including a likely modulation of pineal melatonin secretion and normalisation of circadian and neuroendocrine rhythms [1]. At the molecular level, short peptides of this type can enter the cell and nucleus and, as proposed, interact directly with regions of DNA to influence gene expression. The details of this mechanism remain a subject of research and are not conclusively proven [1].
What the research shows
The bulk of the data is preclinical (cell cultures and laboratory animals). A classic 2003 study demonstrated telomerase activation and telomere lengthening in human somatic cells in vitro [2]. In studies on HER-2/neu transgenic mice, giving Epitalon slowed signs of ageing and reduced the development of mammary adenocarcinomas, and increased the share of tumour-free animals [3]. In experiments on SHR mice the peptide affected ageing biomarkers and lifespan measures without increasing the spontaneous tumour rate [4].
The methodological limits deserve emphasis: much of the research was done mainly by one scientific school, often on small samples, and there are still no large independent randomised clinical trials confirming that Epitalon safely and reliably extends human lifespan or "rejuvenates" through telomeres [1]. So these directions are best read as research hypotheses, not established clinical effects.
Form and handling (research-use)
Longeva supplies Epitalon strictly as a research substance (reagent) with an accompanying certificate of analysis (COA). It is not a medicine and is not intended to diagnose, treat, or prevent any disease in humans or animals.
The typical product form is a white lyophilised powder in a vial, reconstituted with sterile solvent immediately before laboratory use. The lyophilisate is more stable than a ready solution, so it is stored protected from light and moisture, while the reconstituted material is kept cold and used within a short window. Handling, storage, and disposal must follow internal laboratory safety rules and applicable law; all work with the reagent is done by qualified personnel under controlled in vitro and preclinical conditions.